Reporting of adverse events of treatment interventions in multiple myeloma: an overview of systematic reviews

Ref ID 1038
First Author M. Mainou
Journal ANNALS OF HEMATOLOGY
Year Of Publishing 2024
URL https://link.springer.com/article/10.1007/s00277-023-05517-7
Keywords Harms
Oncology
Low methodological quality
Problem(s) No registered or published protocol
Low methodological (AMSTAR) quality
Risk of bias not incorporated into conclusions of review
Conflicts of interest or funding of included studies not assessed
Reasons for excluding potentially eligible studies not provided
Number of systematic reviews included 23
Summary of Findings Of the 23 included 7 SRs ,14.7% examined cardiovascular adverse events, 9 focused on infections, 3 studied thromboembolism and 4 more reviews focused on bortezomib-associated neurotoxicity, carfilzomib-associated renal toxicity, or second primary malignancies. The quality of included studies as judged by AMSTAR 2 was mostly critically low. None of the reviews provided a list of excluded studies, or reported on the sources of funding of studies, only 1 review assessed the potential impact of risk of bias in individual studies on the results of the meta-analysis, and 9 reviews (39.1%) did not have an a priori registered protocol.
Did the article find that the problem(s) led to qualitative changes in interpretation of the results? Not Applicable
Are the methods of the article described in enough detail to replicate the study?